# A Review on Artificial Intelligence in Drug Discovery: Recent Advances and Future Perspective

 

**Authors (@slack): **Popoola Opeyemi Emmanuel (@Emmanuel), Ameenat Oloko (@Ameenat), and Deborah Abolarinwa (@Achiever01).

**Video Link:**

**GitHub Repository:**

** **

**Introduction**

Deep learning, a subset of machine learning that utilises artificial neural networks has garnered significant attention in drug development due to its ability to automatically extract information from data and display complex, non-linear relationships. This is in addition to conventional machine-learning methods that use molecular descriptors generated by humans. The rebirth of deep learning in drug discovery has accelerated the development of novel approaches and applications that will benefit several domains in cheminformatics.

 

**Cutting-edge Uses of Artificial Intelligence**

** **

<!--[if !supportLists]-->**1.  **<!--[endif]-->**QSAR/QSPR and Structure-Based Modeling**

** **

<!--[if !supportLists]-->•       <!--[endif]-->Automatic Feature Extraction, removing the need for manual feature engineering. This enables them to capture complex, nonlinear relationships that conventional quantitative structure-activity relationships/quantitative structure-property relationships (QSAR/QSPR) methods might overlook.

 

<!--[if !supportLists]-->•       <!--[endif]-->Graph Neural Networks, allowing them to learn complex interactions between atoms and bonds. Valuable for predicting biological activity and other properties derived from molecular structures.

<!--[if !supportLists]-->•       <!--[endif]-->Multitask Learning, allowing a single model to predict multiple related outcomes simultaneously. This maximises data efficiency and can enhance predictive accuracy across different tasks.

 


# <!--[if !supportLists]-->2.  <!--[endif]-->De Novo Chemical Design

** **

<!--[if !supportLists]-->•       <!--[endif]-->Generative Models like variational autoencoders (VAEs) and generative adversarial networks (GANs) can create new molecular structures by learning from the distribution of existing compounds. This enables the design of novel candidates that fulfil specific requirements.

 

<!--[if !supportLists]-->•       <!--[endif]-->Rule-free design of bioactive molecules that enables the exploration of wider chemical space by not being restricted to predefined synthetic rules, fostering the discovery of novel compounds.

 

<!--[if !supportLists]-->•       <!--[endif]-->Optimisation of multiple Properties simultaneously such as potency and selectivity, through multitask learning.

 


# <!--[if !supportLists]-->3.  <!--[endif]-->Synthesis Prediction

** **

<!--[if !supportLists]-->•       <!--[endif]-->Automated Synthesis Planning which predicts feasible synthetic pathways for new compounds, and is essential for confirming that designed molecules can be practically synthesised.

 

<!--[if !supportLists]-->•       <!--[endif]-->Data-driven insights which allow for the identification of patterns in chemical reactions and synthesis pathways, leading to more informed predictions about the feasibility of synthesising new compounds

 

<!--[if !supportLists]-->•       <!--[endif]-->Enhanced Predictive Performance which is essential for the practical application of de novo designs in drug discovery.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

<!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t75"
  coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
  filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image1.jpeg" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;left:0;text-align:left;margin-left:66pt;
  margin-top:15.55pt;width:480pt;height:355.8pt;z-index:251659264;visibility:visible;
  mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
  mso-width-relative:margin;mso-height-relative:margin'>
  <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_229/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--><!--[if !vml]-->

|   |                                                                                                                           |
| - | ------------------------------------------------------------------------------------------------------------------------- |
|   |                                                                                                                           |
|   | ![](file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_229/AC/Temp/msohtmlclip1/01/clip_image002.jpg) |

<!--[endif]-->

<!--[if gte vml 1]></o:wrapblock><![endif]-->

\


Figure 1. Diagram showing the transition between classical and modern methodologies for some relevant problems in drug discovery, such as QSAR/QSPR modeling, de novo drug design, and synthesis planning (Jiménez-Luna _et al_., 2021).

\


 


# Current Shortcomings of AI Tools in Drug Discovery

** **

<!--[if !supportLists]-->1.      <!--[endif]-->Data Quality and Availability

 

<!--[if !supportLists]-->2.      <!--[endif]-->Interpretability

 

<!--[if !supportLists]-->3.      <!--[endif]-->Integration with Existing Workflows

 

<!--[if !supportLists]-->4.      <!--[endif]-->Limited Understanding of Complex Biological Systems

 

<!--[if !supportLists]-->5.      <!--[endif]-->Ethical and Regulatory Concerns

 


# Future Transformations in Computer-Assisted Drug Discovery

** **

<!--[if !supportLists]-->1.      <!--[endif]-->Enhanced Data Sharing and Management

 

<!--[if !supportLists]-->2.      <!--[endif]-->Enhanced Interpretability

 

<!--[if !supportLists]-->3.      <!--[endif]-->Integration of Multi-Omics Data

 

<!--[if !supportLists]-->4.      <!--[endif]-->Hybrid Approaches

 

<!--[if !supportLists]-->5.      <!--[endif]-->Ethical Frameworks and Guidelines

 

<!--[if !supportLists]-->6.      <!--[endif]-->Accelerated Drug Development

 


# Conclusion

Advanced QSAR modelling, molecular design, and synthesis planning are transforming AI applications in drug discovery and design, with cross-disciplinary study and deep learning making it easier to create drugs.

 


# Reference

Jiménez-Luna, J., Grisoni, F., Weskamp, N., and Schneider, G. (2021). Artificial intelligence in drug discovery: recent advances and future perspectives. _Expert Opinion on Drug Discovery_, **16**(9): 949–959. https\://doi.org/10.1080/17460441.2021.1909567

\


 
